Is mitral valve prolapse a congenital condition?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Mitral Valve Prolapse a Congenital Condition?

Mitral valve prolapse is not typically a congenital (born with) disease, but rather a condition that develops later in life, most commonly becoming clinically manifest in the third and fourth decades of life, though it can have genetic/familial predisposition. 1

Timing of Disease Manifestation

  • MVP is predominantly considered a heritable disorder with clinical manifestations not present at birth, but appearing later in life. 2
  • The condition most commonly becomes clinically apparent between ages 20-40 years, with severe manifestations typically occurring after age 50. 1, 3
  • In patients who eventually develop severe mitral regurgitation from MVP, the pre-existing heart murmur is first detected at an average age of 34 years, and patients remain asymptomatic for an average of 25 years before symptoms develop. 3

Etiology and Pathophysiology

MVP is mostly associated with myxomatous degeneration of the valve, which represents an acquired degenerative process rather than a congenital malformation. 4, 5

  • The condition preferentially occurs in patients of tall stature and shows familial clustering, indicating genetic predisposition rather than congenital structural abnormality. 4
  • Though variant genes may initiate the development of MVP, the precise phenotypic expression is related to multiple molecular, genetic, and epigenetic factors that modify disease expression over time. 2
  • MVP can be familial or sporadic, isolated (non-syndromic) or part of well-defined syndromes of heritable connective tissue disorders. 2

Distinction from True Congenital Mitral Valve Abnormalities

Isolated congenital mitral valve abnormalities are relatively uncommon and are distinct entities from MVP. 4

True congenital mitral valve lesions include:

  • Cleft mitral valve 4
  • Double-orifice mitral valve 4
  • Parachute mitral valve variants 4
  • Congenital mitral valve stenosis with annular hypoplasia 4
  • Supravalvular or intravalvular mitral ring 4

Key Distinguishing Features

The mitral valve prolapse seen in rheumatic fever patients differs fundamentally from the redundant, myxomatous mitral valve and prolapse seen with Barlow syndrome (classic MVP). 4

  • In rheumatic valvulitis, only the coapting portion of the anterior mitral valve leaflet tip prolapses without billowing of the medial portion or body of the leaflet. 4
  • In contrast, myxomatous MVP (Barlow disease) involves excessive leaflet tissue with redundant, floppy valves showing extensive myxomatous changes with collagen dissolution. 3

Clinical Implications

  • MVP affects 2-3% of the general population and occurs in a heterogeneous group of patients with varying and age-dependent expressions. 2
  • The condition has a wide range of phenotypic expression from asymptomatic to severe complications including mitral regurgitation requiring surgery, heart failure, arrhythmias, and sudden cardiac death. 2
  • Most patients with MVP have minimal symptoms and a benign course, with the majority requiring no treatment other than reassurance. 1

References

Research

Mitral valve prolapse.

Disease-a-month : DM, 1980

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Mitral Regurgitation: Clinical Overview and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.